XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)

    NEXT STORY
    PM360 Magazine Announces Winners of 2019 Trailblazer Awards
    PREV STORY
    Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial

    author_avatar
    NASDAQ Market News

    New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2018

    Presentations will feature data on 1) the company’s Antigen Seeding Technology (AST) platform, and ...

    author_avatar
    NASDAQ Market News

    Innovation Pharmaceuticals Provides Update on Clinical Trials and Revenue Potential of Brilacidin in Inflammatory Bowel Diseases

    author_avatar
    NASDAQ Market News